Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlethora Solutions Holdings Plc Regulatory News (PLE)

  • There is currently no data for PLE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Issue of Equity

8 Dec 2008 07:00

RNS Number : 6769J
Plethora Solutions Holdings PLC
08 December 2008
 



Embargoed Release: Monday 8 December 2008

Plethora Solutions Holdings plc

("Plethora" or "the Company")

Additional funding of £1m

Plethora Solutions Holdings PLC ("Plethora", AIM : PLE), the specialist developer of products for the treatment and management of urological disorders, today announces it has raised £420,215 by way of a placing of 2,801,436 new ordinary shares of 1p each ('Placing Shares') in the Company at a price of 15p per share This placing represents the maximum number of shares available under existing s89 shareholder authority. In addition the Company will shortly receive approximately £560,000 as an advance payment from a trade partner.

The combined cash inflows of approximately £1m before costs will enable the Company to continue to work towards the commercialisation of its assets, particularly the continuing development of PSD502 for the treatment of premature ejaculation on which there has been a separate announcement this morning.

The placing is conditional on the Placing Shares being admitted to trading on AIM, following which Plethora will have a total issued share capital of 30,815,801 ordinary shares. Application has been made for the Placing Shares to be admitted to trading on AIM, and it is expected that Admission will become effective and dealings in the Placing Shares will commence on 12 December 2008. 

Enquiries:

Plethora Solutions

Steven Powell

Tel : +44(0) 20 3077 5400

FinnCap

Geoff Nash

Tel: +44(0) 20 7600 1658

Hansard Group

Adam Reynolds/John Bick

Tel: +44(0) 20 7245 1100

About Plethora:

Plethora is focused on the development and marketing of products for the treatment of urological disorders. The Company has products in clinical development for the treatment of overactive bladder, stress urinary incontinence, interstitial cystitis, gynaecological pain, erectile dysfunction and premature ejaculation. Plethora has a US subsidiary, Timm Medical Technologies Inc, which markets products for the treatment of erectile dysfunction (ED) to urology clinics through a US national sales operation. The Company is headquartered in the UK and is listed on the London Stock Exchange (AIM:PLE) 

Further information is available at www.plethorasolutions.co.uk

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOEFSDFWISASEIE
Date   Source Headline
30th Sep 20087:00 amRNSInterim Results
30th Sep 20087:00 amRNSClinical Update - PSD502
11th Aug 20087:00 amRNSBoard Change
21st Jul 20082:20 pmRNSHolding(s) in Company
1st Jul 20087:05 amRNSDirector/PDMR Shareholding
1st Jul 20087:00 amRNSChange of Adviser
27th Jun 20087:00 amRNSBoard Change
23rd Jun 20082:44 pmRNSAGM Statement
19th Jun 20087:00 amRNSClinical Update PSD502 Phase
22nd May 200810:00 amRNSAnnual Report and Accounts
29th Apr 20087:00 amRNSFinal Results
24th Apr 20087:00 amRNSClinical Update - PSD508
21st Apr 200811:13 amRNSNotice of Results
1st Apr 20087:01 amRNSRe $28m Financing
10th Mar 20085:49 pmRNSHolding(s) in Company
5th Feb 20087:00 amRNSClinical Update - PSD506
10th Jan 200810:39 amRNSChange of Registered Office
19th Dec 20077:01 amRNSClinical Update - PSD502
6th Dec 20077:00 amRNSClinical Update - PSD508
29th Nov 20077:01 amRNSClinical Update PSD503
30th Oct 200712:30 pmBUSSciele Pharma and Plethora Solutions Holdings PLC Announce Initiation of Pivotal Phase III Trials for PSD502 for Premature Ejaculation
30th Oct 20077:01 amRNSClinical Update PSD502 Ph III
8th Oct 20077:00 amRNSClinical Update PSD597
26th Sep 20077:02 amRNSInterim Results
25th Sep 20074:55 pmRNSHolding(s) in Company
10th Sep 20079:27 amRNSNotice of Results
6th Sep 20077:01 amRNSClinical Update PSD597
16th Aug 20072:44 pmRNSAIM Rule 26
12th Jul 20077:01 amRNSClinical Update - PSD502
10th Jul 20074:11 pmRNSResult of AGM
2nd Jul 20073:14 pmRNSDirector/PDMR Shareholding
2nd Jul 20077:01 amRNSProduct Update - Invicorp
29th Jun 20071:20 pmRNSTotal Voting Rights
29th Jun 200710:29 amRNSShare Options Award
25th Jun 20077:01 amRNSClinical Update PSD597 for IC
14th Jun 20074:46 pmRNSHolding(s) in Company
14th Jun 20074:39 pmRNSHolding(s) in Company
1st Jun 200710:00 amRNSDirectorate Change
30th May 20077:01 amRNSPreliminary Results
24th May 20071:00 pmBUSSciele Enters Into Exclusive License Agreement with Plethora Solutions Limited to Market PSD502 for the Treatment of Premature Ejaculation
24th May 20077:05 amRNSNotice of Results
24th May 20077:03 amRNSLicensing deal
8th May 20077:02 amRNSProduct Acquisitions
5th Apr 20077:36 amRNSAcquisition
21st Mar 20075:05 pmRNSHolding(s) in Company
21st Mar 20075:05 pmRNSHolding(s) in Company
21st Mar 20075:04 pmRNSHolding(s) in Company
13th Mar 20071:08 pmRNSHolding(s) in Company
12th Mar 20072:16 pmRNSExercise of share options
1st Mar 20077:03 amRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.